Am J Ther
When pain relief meets anticoagulation: navigating DOAC–NSAID bleeding risk
Clinical Takeaway: Avoid reflexively banning NSAIDs in patients on DOACs—individualized risk assessment, dose, duration, and patient factors should guide decisions.
Concomitant NSAID use increases bleeding risk by about 50% in patients on DOACs, yet real-world guidance on how to manage this common combination remains limited.
In this structured clinical review, investigators analyzed pharmacologic, trial, and real-world data from 2005–2024 to clarify bleeding risks when NSAIDs are co-prescribed with DOACs. Across multiple observational cohorts, adding an NSAID to a DOAC increased overall bleeding risk by roughly 40% to 60%, with GI bleeding risk often doubling, while effects on major bleeding were less consistent.
Risk was amplified by advanced age, chronic kidney disease, active cancer, autoimmune disease, and prolonged or high-dose NSAID use. Authors also highlight potential pharmacokinetic interactions involving CYP3A4 and P-glycoprotein, particularly for rivaroxaban and apixaban, although real-world clinical impact remains incompletely defined.
Importantly, the authors stress nuance over absolutism. As they note, “the clinical message should not be a blanket prohibition of NSAID use in anticoagulated patients.” Instead, they recommend the lowest effective NSAID dose, shortest duration, gastroprotection when appropriate, and heightened vigilance in special populations where bleeding consequences are greatest.
Source: Mameli A, et al. (2026, Mar-Apr). Am J Ther. Drug Interactions Between Direct Oral Anticoagulants and Nonsteroidal Anti-inflammatory Drugs: A Clinical Risk-Benefit Analysis With Focus on Special Populations